Larisa M. Kolpakchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Larisa M. Kolpakchi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Inessa D. Fedonyuk
Russian Children's Clinical Hospital, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3 shared publications - Lyudmila Mikhailovna Kuzenkova
National Medical Research Center for Children's Health, Ministry of Health of Russia
3 shared publications - Yulia A. Kursakova
Russian Children's Clinical Hospital, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3 shared publications - Ada R. Artemenko
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
2 shared publications - Aleksandra A. Nezhelskaya
National Medical Research Center for Children’s Health
2 shared publications - Anastasia A. Kozyreva
Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- 10 December 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (6)
Subacute sclerosing panencephalitis in children: series of clinical case reports
Subacute sclerosing panencephalitis (SSPE) is a rare complication caused by persistent measles infection and characterized by a decline in cognitive functions and severe motor impairments. Since SSPE is considered a potentially fatal complication of acute measles infection and is typically develops in young individuals especially those infected prior to the age of two years old, special attention must be paid to the implementation of vaccination programs that can prevent severe disease. Thus, the purpose of this research was to present the demographic and clinical characteristics of pediatric patients with SSPE in order to enhance its early diagnosis and to raise the pediatricians' awareness of this serious measles complication. In this series of case reports Authors represent the clinical picture, laboratory and instrumental data of six children with SSPE admitted at the Russian Children's Clinical Hospital with the Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Moscow, Russia) in Aug. 2022-Aug. 2024. Authors have conducted an analysis of complaints, clinical symptoms, laboratory, neurophysiological and neuroimaging data of 6 patients with SSPE. All patients have undergone cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI) of the brain and video EEG monitoring during both wakefulness and sleep at the time of diagnosis. Currently, there is no specific treatment for SSPE that would either lead to symptom regression or prevent the related disability. Therefore, vaccination remains the only effective means for the SSPE prevention.
- 10 December 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (6)
Subacute sclerosing panencephalitis in children: series of clinical case reports
Subacute sclerosing panencephalitis (SSPE) is a rare complication caused by persistent measles infection and characterized by a decline in cognitive functions and severe motor impairments. Since SSPE is considered a potentially fatal complication of acute measles infection and is typically develops in young individuals especially those infected prior to the age of two years old, special attention must be paid to the implementation of vaccination programs that can prevent severe disease. Thus, the purpose of this research was to present the demographic and clinical characteristics of pediatric patients with SSPE in order to enhance its early diagnosis and to raise the pediatricians' awareness of this serious measles complication. In this series of case reports Authors represent the clinical picture, laboratory and instrumental data of six children with SSPE admitted at the Russian Children's Clinical Hospital with the Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Moscow, Russia) in Aug. 2022-Aug. 2024. Authors have conducted an analysis of complaints, clinical symptoms, laboratory, neurophysiological and neuroimaging data of 6 patients with SSPE. All patients have undergone cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI) of the brain and video EEG monitoring during both wakefulness and sleep at the time of diagnosis. Currently, there is no specific treatment for SSPE that would either lead to symptom regression or prevent the related disability. Therefore, vaccination remains the only effective means for the SSPE prevention.
- 11 March 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (2) , 58-68
Modern aspects of diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy in children
OBJECTIVE Analysis of demographic, clinical, laboratory, electrophysiological and neuroimaging data and pathogenetic therapy of pediatric patients with chronic inflammatory demyelinating polyneuropathy (CIDP). MATERIAL AND METHODS Patients (n=30) were observed in a separate structural unit of the Russian Children’s Clinical Hospital of the Russian National Research Medical University named after. N.I. Pirogova Ministry of Health of the Russian Federation in the period from 2006 to 2023. The examination was carried out in accordance with the recommendations of the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society on the Management of CIDP (2021). All patients received immunotherapy, including intravenous immunoglobulin (IVIG) (n=1), IVIG and glucocorticosteroids (GCS) (n=17, 56.7%), IVIG+GCS+plasmapheresis (n=12, 40.0%). Alternative therapy included cyclophosphamide (n=1), cyclophosphamide followed by mycophenolate mofetil (n=1), rituximab (n=2, 6.6%), azathioprine (n=3), mycophenolate mofetil (n=2, 6.6%). RESULTS In all patients, there was a significant difference between scores on the MRCss and INCAT functional scales before and after treatment. At the moment, 11/30 (36.6%) patients are in clinical remission and are not receiving pathogenetic therapy. The median duration of remission is 48 months (30—84). The longest remission (84 months) was observed in a patient with the onset of CIDP at the age of 1 year 7 months. CONCLUSION Early diagnosis of CIDP is important, since the disease is potentially curable; early administration of pathogenetic therapy provides a long-term favorable prognosis.
- 11 March 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (2) , 58-68
Modern aspects of diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy in children
OBJECTIVE Analysis of demographic, clinical, laboratory, electrophysiological and neuroimaging data and pathogenetic therapy of pediatric patients with chronic inflammatory demyelinating polyneuropathy (CIDP). MATERIAL AND METHODS Patients (n=30) were observed in a separate structural unit of the Russian Children’s Clinical Hospital of the Russian National Research Medical University named after. N.I. Pirogova Ministry of Health of the Russian Federation in the period from 2006 to 2023. The examination was carried out in accordance with the recommendations of the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society on the Management of CIDP (2021). All patients received immunotherapy, including intravenous immunoglobulin (IVIG) (n=1), IVIG and glucocorticosteroids (GCS) (n=17, 56.7%), IVIG+GCS+plasmapheresis (n=12, 40.0%). Alternative therapy included cyclophosphamide (n=1), cyclophosphamide followed by mycophenolate mofetil (n=1), rituximab (n=2, 6.6%), azathioprine (n=3), mycophenolate mofetil (n=2, 6.6%). RESULTS In all patients, there was a significant difference between scores on the MRCss and INCAT functional scales before and after treatment. At the moment, 11/30 (36.6%) patients are in clinical remission and are not receiving pathogenetic therapy. The median duration of remission is 48 months (30—84). The longest remission (84 months) was observed in a patient with the onset of CIDP at the age of 1 year 7 months. CONCLUSION Early diagnosis of CIDP is important, since the disease is potentially curable; early administration of pathogenetic therapy provides a long-term favorable prognosis.
- Open Access
- 18 April 2022
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 14 (2) , 117-125
Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea
Botulinum therapy for cerebral palsy (CP) is considered not only as one of the effective approaches for the treatment of increased muscle tone and spasticity, but also as a method of excessive salivation correction. The article presents an overview of the results of Russian and foreign studies on the efficacy and safety of incobotulinumtoxinA for the treatment of spasticity of the lower and upper limbs, as well as sialorrhea in patients with CP. The article also provides a consensus opinion of Russian specialists working with patients with CP and using Xeomin (incobotulinumtoxinA) in their practice for the treatment of spasticity and sialorrhea. This consensus was based on the results of a Russian retrospective multicenter study on the use of incobotulinumtoxinA for the treatment of spasticity and sialorrhea in CP, data from recently published international clinical trials, and our own clinical experience. We present detailed practical recommendations on the calculation of the total dose of incobotulinumtoxinA per procedure for the treatment of spasticity in CP, on the calculation of incobotulinumtoxinA dose for the most common target muscles (lower and upper limbs) for spasticity treatment in CP, on incobotulinumtoxinA dilution and dose calculation for sialorrhea treatment in children, on incobotulinumtoxinA dilution and dose calculation for simultaneous treatment of spasticity and sialorrhea in CP. We justify incobotulinumtoxinA use, when simultaneous treatment of spasticity and sialorrhea is necessary, which allows reducing the intervals between repeated injection cycles. IncobotulinumtoxinA use in children with CP demonstrates a favorable safety profile, including long-term use.
- 18 April 2022
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 14 (2) , 117-125
Open AccessRussian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea
Botulinum therapy for cerebral palsy (CP) is considered not only as one of the effective approaches for the treatment of increased muscle tone and spasticity, but also as a method of excessive salivation correction. The article presents an overview of the results of Russian and foreign studies on the efficacy and safety of incobotulinumtoxinA for the treatment of spasticity of the lower and upper limbs, as well as sialorrhea in patients with CP. The article also provides a consensus opinion of Russian specialists working with patients with CP and using Xeomin (incobotulinumtoxinA) in their practice for the treatment of spasticity and sialorrhea. This consensus was based on the results of a Russian retrospective multicenter study on the use of incobotulinumtoxinA for the treatment of spasticity and sialorrhea in CP, data from recently published international clinical trials, and our own clinical experience. We present detailed practical recommendations on the calculation of the total dose of incobotulinumtoxinA per procedure for the treatment of spasticity in CP, on the calculation of incobotulinumtoxinA dose for the most common target muscles (lower and upper limbs) for spasticity treatment in CP, on incobotulinumtoxinA dilution and dose calculation for sialorrhea treatment in children, on incobotulinumtoxinA dilution and dose calculation for simultaneous treatment of spasticity and sialorrhea in CP. We justify incobotulinumtoxinA use, when simultaneous treatment of spasticity and sialorrhea is necessary, which allows reducing the intervals between repeated injection cycles. IncobotulinumtoxinA use in children with CP demonstrates a favorable safety profile, including long-term use.
- 25 December 2021
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 2 (4) , 189-202
Dose selection of Incobotulinumtoxin A for the treatment of spasticity and sialorrhea in cerebral palsy: results of a retrospective multicenter study
Introduction. In patients with infantile cerebral palsy (CP), botulinum therapy is used to treat both muscle tone disorders and sialorrhea. Therefore, it is logical to use one preparation of botulinum toxin type A to treat spasticity and sialorrhea in one injection procedure. The aim of the work is to conduct a retrospective analysis of data from 15 centres that treat patients with cerebral palsy and use the botulinum therapy method to determine the optimal doses of IncobotulinumtoxinA (IBTA) for the treatment of spasticity and chronic sialorrhea in real clinical practice. Materials and methods. The treatment results of 389 children with cerebral palsy (including 211 (54.2%) boys) with IBTA were analyzed. The majority were children with bilateral forms of cerebral palsy - 312 (80.2%). The average age of the patients was 5.27 ± 3.71 years, the average weight of the patients was 18.8 ± 10.9 kg. Results. The total dose of IBTA in the group of 389 patients with cerebral palsy for the treatment of spasticity was 163.74 ± 80.65 U (25-550; 95% CI 155.7-171.7) and 10.4 ± 5.4 U/kg body weight (1,25-29.7; 95% CI 9.8-10.9). The total dose of IBTA in the group of patients with cerebral palsy with simultaneous treatment of spasticity and chronic sialorrhea (n = 16) was significantly higher: 267.18 ± 124.57 U (115-570; 95% CI 200.8-333.6) and 13, 0 ± 7.1 U/kg (5.8-24.6; 95% CI 9.2-16.8). In the lower extremities, the most frequent target muscles were the gastrocnemius (55.0% of cases; 95% CI 49.9-60.0) and semitendinosus / semimembranous muscle (46.3% of cases; 95% CI 41.2-51.4 ), and in the upper limbs - pronator teres (48.6% of cases; 95% CI 43.5-53.7) and biceps brachii (28.8% of cases; 95% CI 24.3-33.6). Limitations of the study. The limitations of our work are the use of an open retrospective study format, a relatively small sample of patients with chronic sialorrhea, the absence of long-term follow-up of patients and the results of repeated IBTA injections. Conclusion. If it is necessary to use botulinum therapy for the treatment of spasticity and sialorrhea in a child with CP, it is optimal to use the product IncobotulinumtoxinA, which will allow correction of two pathological manifestations in one procedure and can shorten the intervals between repeated injection cycles.
- 25 December 2021
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 2 (4) , 189-202
Dose selection of Incobotulinumtoxin A for the treatment of spasticity and sialorrhea in cerebral palsy: results of a retrospective multicenter study
Introduction. In patients with infantile cerebral palsy (CP), botulinum therapy is used to treat both muscle tone disorders and sialorrhea. Therefore, it is logical to use one preparation of botulinum toxin type A to treat spasticity and sialorrhea in one injection procedure. The aim of the work is to conduct a retrospective analysis of data from 15 centres that treat patients with cerebral palsy and use the botulinum therapy method to determine the optimal doses of IncobotulinumtoxinA (IBTA) for the treatment of spasticity and chronic sialorrhea in real clinical practice. Materials and methods. The treatment results of 389 children with cerebral palsy (including 211 (54.2%) boys) with IBTA were analyzed. The majority were children with bilateral forms of cerebral palsy - 312 (80.2%). The average age of the patients was 5.27 ± 3.71 years, the average weight of the patients was 18.8 ± 10.9 kg. Results. The total dose of IBTA in the group of 389 patients with cerebral palsy for the treatment of spasticity was 163.74 ± 80.65 U (25-550; 95% CI 155.7-171.7) and 10.4 ± 5.4 U/kg body weight (1,25-29.7; 95% CI 9.8-10.9). The total dose of IBTA in the group of patients with cerebral palsy with simultaneous treatment of spasticity and chronic sialorrhea (n = 16) was significantly higher: 267.18 ± 124.57 U (115-570; 95% CI 200.8-333.6) and 13, 0 ± 7.1 U/kg (5.8-24.6; 95% CI 9.2-16.8). In the lower extremities, the most frequent target muscles were the gastrocnemius (55.0% of cases; 95% CI 49.9-60.0) and semitendinosus / semimembranous muscle (46.3% of cases; 95% CI 41.2-51.4 ), and in the upper limbs - pronator teres (48.6% of cases; 95% CI 43.5-53.7) and biceps brachii (28.8% of cases; 95% CI 24.3-33.6). Limitations of the study. The limitations of our work are the use of an open retrospective study format, a relatively small sample of patients with chronic sialorrhea, the absence of long-term follow-up of patients and the results of repeated IBTA injections. Conclusion. If it is necessary to use botulinum therapy for the treatment of spasticity and sialorrhea in a child with CP, it is optimal to use the product IncobotulinumtoxinA, which will allow correction of two pathological manifestations in one procedure and can shorten the intervals between repeated injection cycles.
- Open Access
- 6 December 2020
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 10 (3) , 35-41
The efficacy and safety of nusinersen within the expanded access program in Russia
Introduction. Spinal muscular atrophy is a severe neuromuscular disease characterized by rapid progression of muscle weakness and early death. Pathogenetic therapy with nusinersen can significantly change the course of the disease and enable the patient to acquire new skills. The study of the efficacy and safety of nusinersen therapy in patients with type 1 spinal muscular atrophy should be continued. The aim of the study was to assess the safety and efficacy of nusinersen therapy in patients with type 1 spinal muscular atrophy for 6 months as part of an expanded access program at federal and regional healthcare facilities. Materials and methods. Patients with type 1 spinal muscular atrophy received nusinersen therapy under the expanded access program (NCT02865109). Patients were evaluated before starting treatment and 6 months after starting treatment. Overall motor development and motor function was assessed using the Hammersmith Infant Neurological Status Scale Part 2 and the Philadelphia Pediatric Hospital Neonatal Motor Scale. Results. 41 children aged 6 to 38 months received nusinersen therapy between July 2019 and March 2020. At the time of analysis, all patients were alive and continued treatment. The average improvement on the Hammersmith Hospital Neurological Status Scale was 3.7 points after 6 months of therapy compared to baseline (n = 39, p 0.001). The mean improvement on the Children’s Hospital of Philadelphia Scale for the Diagnosis of Motor Function in Newborns was 9.8 after 6 months of therapy from baseline (n = 30, p 0.001). Conclusion. The efficacy and safety of nusinersen have been demonstrated in real clinical practice in Russia in the treatment of early-onset spinal muscular atrophy.
- 6 December 2020
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 10 (3) , 35-41
Open AccessThe efficacy and safety of nusinersen within the expanded access program in Russia
Introduction. Spinal muscular atrophy is a severe neuromuscular disease characterized by rapid progression of muscle weakness and early death. Pathogenetic therapy with nusinersen can significantly change the course of the disease and enable the patient to acquire new skills. The study of the efficacy and safety of nusinersen therapy in patients with type 1 spinal muscular atrophy should be continued. The aim of the study was to assess the safety and efficacy of nusinersen therapy in patients with type 1 spinal muscular atrophy for 6 months as part of an expanded access program at federal and regional healthcare facilities. Materials and methods. Patients with type 1 spinal muscular atrophy received nusinersen therapy under the expanded access program (NCT02865109). Patients were evaluated before starting treatment and 6 months after starting treatment. Overall motor development and motor function was assessed using the Hammersmith Infant Neurological Status Scale Part 2 and the Philadelphia Pediatric Hospital Neonatal Motor Scale. Results. 41 children aged 6 to 38 months received nusinersen therapy between July 2019 and March 2020. At the time of analysis, all patients were alive and continued treatment. The average improvement on the Hammersmith Hospital Neurological Status Scale was 3.7 points after 6 months of therapy compared to baseline (n = 39, p 0.001). The mean improvement on the Children’s Hospital of Philadelphia Scale for the Diagnosis of Motor Function in Newborns was 9.8 after 6 months of therapy from baseline (n = 30, p 0.001). Conclusion. The efficacy and safety of nusinersen have been demonstrated in real clinical practice in Russia in the treatment of early-onset spinal muscular atrophy.
- Open Access
- 5 July 2019
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 11 (2) , 164-174
Early infantile epileptic encephalopathy type 4: clinical, neurophysiological and therapeutic aspects
Early infantile epileptic encephalopathy type 4: clinical, neurophysiological and therapeutic aspects
- 5 July 2019
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 11 (2) , 164-174
Open AccessEarly infantile epileptic encephalopathy type 4: clinical, neurophysiological and therapeutic aspects
Early infantile epileptic encephalopathy type 4: clinical, neurophysiological and therapeutic aspects